Amphetamine Stimulant Prodrug denied as non-formulary by Cigna?

Cigna's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issues Non-Formulary Denials for Amphetamine Stimulant Prodrugs

Cigna's formulary tiers stimulant medications based on plan design and contract structure. An amphetamine prodrug may be excluded from the formulary or placed on a non-covered tier even when it is the clinically optimal choice for a given patient. The denial communicates that the plan will not pay at the standard benefit level under the current formulary placement — it does not constitute a clinical finding against the drug. A formulary exception appeal redirects the question to whether the covered alternatives are medically appropriate for this specific patient.

## Why This Denial Is Appealable

Non-formulary denials are adverse benefit determinations subject to appeal under ERISA §503 and ACA §2719. For marketplace and fully-insured plans, the ACA requires a formulary exception process when a covered alternative is contraindicated or when covered alternatives have been tried and failed. An IRO has authority to override formulary placement when the clinical record supports it. The external-review window is approximately four months from the denial notice; verify the exact date on your Explanation of Benefits. Mental health parity principles also apply: formulary restrictions on psychiatric medications cannot be more burdensome than those applied to analogous medical/surgical drugs.

## The Concrete Appeal Process

1. Request Cigna's formulary exception criteria. These must be disclosed on request and define the specific grounds on which an exception can be granted. 2. File a formulary exception request alongside or as part of the formal internal appeal, arguing that covered alternatives are medically inadequate for this patient. 3. Invoke mental health parity if Cigna covers comparable non-formulary drugs for other conditions without equivalent barriers. 4. External review is available if the exception is denied internally; IROs evaluate formulary exceptions using independent clinical evidence.

## Documentation to Gather

• Prior formulary-alternative trial records: For each covered stimulant that was tried, provide pharmacy records showing fill dates, chart notes documenting the prescriber's assessment of response, and the specific reason the alternative was discontinued or deemed inadequate.
• Clinical rationale for the prodrug specifically: The prescriber's explanation of why the prodrug formulation — whether its pharmacokinetic profile, duration of action, or tolerability characteristics — is clinically necessary for this patient.
• Contraindication or intolerance documentation: If a covered alternative is contraindicated or not tolerable, document this with chart-specific clinical facts.
• Prescriber letter: A focused statement addressing each formulary-exception criterion with chart citations.

## Criteria-Mapping Strategy

Pull Cigna's formulary exception policy and address each exception ground directly. The most common winning argument is exhaustive documentation of failed formulary alternatives — each alternative should appear with a start date, stop date, and clearly documented reason for failure. Reviewers who see a complete "tried and failed" record have a strong clinical basis to grant the exception; an incomplete record leaves the reviewer with discretion to uphold the denial.